Anitocabtagene autoleucel for treating relapsed or refractory multiple myeloma [ID6549]
Topic prioritisation
To appraise the clinical and cost effectiveness of Anitocabtagene autoleuce (CART-ddBCMA) within its marketing authorisation for
treating multiple myeloma